NASDAQ: INVAInnoviva Inc Stock
$20.92+0.04 (+0.19%)
Updated Aug 15, 2025
INVA Price
$20.92
Fair Value Price
N/A
Market Cap
$1.32B
52 Week Low
$16.67
52 Week High
$22.00
P/E
34.3x
P/B
1.84x
P/S
3.41x
PEG
0.57x
Dividend Yield
N/A
Revenue
$370.23M
Earnings
$38.65M
Gross Margin
86.6%
Operating Margin
23.09%
Profit Margin
10.4%
Debt to Equity
0.87
Operating Cash Flow
$201M
Beta
0.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
INVA Overview
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INVA's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
INVA
Ranked#15 of 482
Ranked#15 of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.15 | A | |
| $39.51 | A | |
| $12.27 | A |
Be the first to know about important INVA news, forecast changes, insider trades & much more!
INVA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INVA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INVA ($20.92) is trading above its intrinsic value of $16.84, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INVA is good value based on its earnings relative to its share price (34.3x), compared to the US market average (35.99x)
P/E vs Market Valuation
INVA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more INVA due diligence checks available for Premium users.
Valuation
INVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
34.3x
Industry
-120.52x
Market
35.99x
INVA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INVA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
INVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.84x
Industry
4.5x
INVA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INVA price to earnings growth (PEG)
For valuing profitable companies with growth potential
INVA is good value based... subscribe to Premium to read more.
PEG Value Valuation
INVA's financial health
Profit margin
Revenue
$100.3M
Net Income
$63.7M
Profit Margin
63.5%
INVA's Earnings (EBIT) of $85.48M... subscribe to Premium to read more.
Interest Coverage Financials
INVA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.3B
Liabilities
$618.8M
Debt to equity
0.87
INVA's short-term assets ($651.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INVA's short-term assets ($651.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INVA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
INVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$44.1M
Investing
$33.1M
Financing
$1.2M
INVA's operating cash flow ($200.62M)... subscribe to Premium to read more.
Debt Coverage Financials
INVA vs Biotech Stocks
Innoviva Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.